The global respiratory syncytial virus (RSV) diagnostic market size was valued at USD 681.8 million in 2016 and is expected to grow at a CAGR of 9.6% during the forecast period. Increasing incidence rate of respiratory infections, rising neonatal population base, increasing demand for in-vitro diagnostics, and increasing demand for point of care facilities are among the key factors driving market growth.
Increasing incidence rate of respiratory infections is driving the market and is likely to increase rapidly over the forecast period. With rising incidences of chronic conditions worldwide, cases of respiratory infections are expected to increase. This is further expected to drive the demand for infectious disease testing market such as RSV. In neonates, these infections are a leading cause of mortality, which can be avoided if timely diagnosis and treatment are available.
According to the document “Reducing Neonatal Mortality And Morbidity In Latin America And The Caribbean, An Interagency Strategic Consensus”, about 400,000 children die by the age of five, of which, 270,000 die in the first year itself. These deaths are caused due to infections that are preventable, and hence, are attracting the focus of health agencies to take due cognizance of such cases. Pan America Health Organization (PAHO) and Latin American Center for Perinatology are focusing on educating parents to initiate preventive measures for possible infections, thereby promoting a hike in RSV diagnostic rate.
Furthermore, rising incidences of childhood pneumonia are also predicted to propel the demand for RSV testing. According to statistics provided by the WHO, about 151.8 million cases of childhood pneumonia were recorded in 2001 in developing countries such as Latin America. It also estimated that about 1.9 million of these cases led to death.
The overall global newborn population base is on a rise and a similar trend is expected to be witnessed over the next seven years. According to the world population meter, over 88 billion births were reported in 2015 resulting in about 250 births per minute. Of these, over 2.8 million babies die within the first month due to infection and lack of screening of the babies for such conditions. To prevent this number from rising, efforts are being taken by organizations such as the WHO, CDC, PAHO, Healthy Newborn Network, etc., to educate parents about the possible disorders and their diagnostic procedures.
Moreover, Latin American agencies have ordered 100% screening of all children born in private sector hospitals. According to the paper entitled “Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia” in the Jornal de Pediatria every one in three cases of lower respiratory tract infection is caused by RSV leading to about 30.0% incidence rate of the infection in the region of Columbia. Therefore, the rising neonatal population base is driving the growth of the market.
Products of the respiratory syncytial virus diagnostics market include direct fluorescent antibody (DFA) method, rapid antigen diagnostic test (RADTs), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, flow cytometry, and others. Chromatographic immunoassay includes gravity-driven test and oligochromatography (OC). Molecular diagnostics accounted for the largest share in 2014 owing to high accuracy of molecular methods over other methods. This method is a gold standard for RSV diagnosis, as it is the most accurate method.
The most commonly used mechanism for molecular diagnosis of RSV is Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and multiplexed nucleic acid amplification. As of 2014-2015, numerous assays have been introduced functioning on molecular diagnostics such as Cepheid Xpert Flu/RSV XC Assay, Simplexa Flu A/B & RSV, and Verigene Respiratory Virus Nucleic Acid Test. Moreover, growth in genomics and proteomics research is expected to roll out new molecular methods for RSV diagnosis.
Rapid Antigen Diagnostic Test (RADT) is anticipated to witness lucrative growth over the forecast period owing to advantages such as quick result time, elimination of ancillary testing, early diagnostic and implementation of treatment, and improving antibiotic stewardship. This is Point-of-Care (POC) test, and hence, can be performed in the emergency department or physician’s office. Additionally, this test detects infected patients early in the course of action, which leaves a positive impact on clinical decisions.
On the basis of end-use, the respiratory syncytial virus diagnostics market is segmented into hospitals, laboratories, clinics, and homecare. Hospitals held the largest share in the market and is expected to dominate the market over the forecast period. As the occurrence of RSV infection is prominent in neonates and infants, the treatment for these demographics has to be controlled with round-the-clock monitoring, and hence, there is high hospitalization in case of RSV infection.
The homecare segment is also anticipated to witness lucrative growth, as home healthcare is a cost-effective alternative over the hospital stay. Moreover, availability of adequate trained staff for home healthcare is expected to support the growth of home healthcare in the RSV diagnostics market.
North America dominated the respiratory syncytial virus diagnostics market in 2014, owing to rising incidences of these infections and an increasing infant population over the forecast period. Molecular diagnostics and chromatographic immunoassays are the popular products used within the region as they provide high accuracy, sensitivity, and specificity, leading to rapid increase in its demand. In order to produce companion diagnostics, increasing number of strategic partnerships between pharmaceutical majors and in vitro diagnostic manufacturing companies is expected to make this a lucrative segment by signaling tremendous potential.
Asia Pacific respiratory syncytial virus diagnostics market is expected to witness the highest growth over the forecast period owing to the high population density and rapidly increasing prevalence of infectious diseases. Strong demand for automated healthcare testing for accurate and faster diagnosis of the diseases is expected to boost the market growth in the region. China, India, Japan, and Malaysia are expected to be the fastest-growing markets in the region due to the developing healthcare systems and growing numbers of government initiatives. Furthermore, rising infant population is expected to propel the growth of the market.
Furthermore, increasing healthcare expenditure in developing countries such as Brazil, Mexico, India, Saudi Arabia, along with supportive government funding are the factors attributing towards the market growth. Presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and rising patient awareness levels are some of the factors accounting for the rapid growth of these regions.
Few of the major players operating in this market include Becton, Dickinson and Company, Novartis Diagnostics, Abbott Laboratories, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Hoffmann La Roche Limited, BioMerieux, DiaSorin SPA, EMD Millipore, Quidel Corporation, Alere Inc., Coris BioConcept, Fast-track Diagnostics, and Quest Diagnostics.
Various strategies such as product launches, and mergers & acquisitions are being adopted by these key market players to increase the outreach of their products and strengthen their product portfolios. For instance, in November 2015, Merck KGaA completed the acquisition of Sigma-Aldrich and coupled it together with EMD Millipore. This is because they form a complementary diagnostic product portfolio along with similar capabilities in innovation. The clubbing is expected to expand the diagnostic capabilities for RSV.
In September 2015, Roche Diagnostics received a CLIA waiver from the U.S. FDA for the detection of flu A/B, RSV, and Strep A using the Cobas Liat System. Post the approval; the system may be used in pharmacy clinics, hospitals, physician offices, and other healthcare providing facilities.
Base year for estimation
Actual estimates/Historical data
2012 - 2015
2016 - 2022
Revenue in USD Million & CAGR from 2012 to 2022
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Brazil, Mexico, Argentina, Peru, South Africa, and Saudi Arabia
Revenue, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2012 to 2022. For the purpose of this study, Grand View Research, Inc. has segmented the respiratory syncytial virus diagnostics market report on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Million, 2012 - 2022)
Direct Fluorescent Antibody (DFA) Method
Rapid Antigen Diagnostic Test (RADTs)
Gravity Driven Test
End-use Outlook (Revenue, USD Million, 2012 - 2022)
Regional Outlook (Revenue, USD Million, 2012 - 2022)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.